A significant new study, presented at the European Association for the Study of Diabetes (EASD 2025) congress, has revealed that immunity to the Hepatitis B virus (HBV) may significantly lower the risk of developing type 2 diabetes. According to the research findings, individuals with high levels of HBV antibodies exhibited a substantially reduced incidence of diabetes, with the risk potentially decreasing by as much as 43 percent.
Scientists analyzed extensive data from the TriNetX database, focusing on adults with no prior history of either Hepatitis B or diabetes. A comparative analysis between groups that possessed HBV immunity and those that did not demonstrated a 15 percent lower risk of diabetes in the HBV-protected cohort. Furthermore, this protective effect was found to be dose-dependent, intensifying with higher antibody concentrations. A 19 percent reduction in risk was observed at antibody levels of ≥100 mIU/mL, escalating to an impressive 43 percent reduction when concentrations reached ≥1000 mIU/mL.
The most pronounced protective action was evident among younger adults aged 18-44, who showed a 20 percent lower risk compared to their age-matched peers lacking HBV immunity. While a beneficial effect also persisted in older individuals, its impact was less significant.
Although this study highlights a strong association rather than proving a direct cause-and-effect relationship, the authors suggest that these compelling results indicate a possible additional benefit of Hepatitis B vaccination. Beyond its primary role in preventing viral infections, vaccination might also contribute to reducing the likelihood of developing type 2 diabetes.
In related prior research, scientists have previously established that type 2 diabetes can directly alter the function of heart muscle, thereby accelerating the progression of heart failure.
